Search

CTCE-0214

CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.

SYNB1353

[A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug.

Desmethylprodine

It is known to be a designer drug, synthesized in 1977, for the purpose of recreational use. Illicit manufacturing has occurred. … Desmethylprodine, a derivative of meperidine, is an opioid analgesic with the potency of morphine.

Desoxycorticosterone pivalate

Desoxycorticosterone pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air.

3-Methylfentanyl

3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000

SNS-032

CRx-139

This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

Nandrolone phenpropionate

C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.

Muraglitazar

Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease